Compare GSK plc (GSK) vs Occidental Petroleum Corporation (OXY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Occidental Petroleum Corporation — how do they compare? GSK plc trades at $52.7 (market cap $101.34B), while Occidental Petroleum Corporation trades at $53.83 (market cap $53.48B). The key difference: GSK plc is the larger of the two by market cap, and GSK plc pays the higher dividend (3.49%). Which is the better fit depends on your goals.
| GSK | OXY | |
|---|---|---|
Market Cap | $101.34B | $53.48B |
Sector | Health | Energy |
52-Week High | $61.18 | $66.24 |
52-Week Low | $36.20 | $38.92 |
Enterprise Value | $121.95B | $74.57B |
Dividend Yield | 3.49% | 1.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.
GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.
Occidental Petroleum (OXY) trades at $54.02, down 1.01% on the day, with a bullish technical signal supported by moving averages. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 results expected on August 5. Recent news highlights improved capital efficiency and debt reduction, while analyst consensus shows 50% buy ratings with a $66.14 price target. Revenue has declined from $36.6B in 2022 to $21.6B in 2025, though net margins remain healthy at 10.77%.
OXY presents a mixed outlook with strong operational performance and analyst optimism offset by declining revenue trends. The stock offers potential upside to consensus targets but faces risks from oil price volatility and execution challenges under new leadership. Key catalysts include Q2 earnings and continued progress on debt reduction initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Occidental Petroleum Corporation
Occidental Petroleum is an independent exploration and production company with operations in the United States, Latin America, and the Middle East. At the end of 2021, the company reported net proved reserves of 3.5 billion barrels of oil equivalent. Net production averaged 1,174 thousand barrels of oil equivalent per day in 2021 at a ratio of 75% oil and natural gas liquids and 25% natural gas.
Read more on OXY →
